Advanced Wound Care and Regenerative Medicine Access and Reform Act

This bill would add skin substitute products, which are materials applied to wounds and meant to stay in the wound, as a covered Medicare Part B benefit and set a single payment rate for them starting in 2026. That rate would be based on a volume-weighted average of 2023 payment limits and would be adjusted each year for inflation, with Medicare paying 80 percent and the same amount regardless of where care is given. The bill would require Medicare to identify the top 3 percent of providers by skin substitute payments, publish the list, refer it to the Inspector General, and apply prepayment review and prior authorization to those providers. It would limit payment to the portion of product used, excluding wastage. It would also direct the Food and Drug Administration to review and consider streamlining approval rules for human cell and tissue products and report to Congress.

Full text and official record on Congress.gov

Sponsors

• Gabe Evans Republican sponsor
• 2 cosponsors